Clinical Trial Update: Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Tc-99m tilmanocept imaging to predict anti-TNFα therapy response in moderate-to-severe rheumatoid arthritis has been terminated, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Lymphoseek (tilmanocept)

Snippet

Sponsor: Navidea Biopharmaceuticals | Conditions: Rheumatoid Arthritis | Phase 3 | Status: TERMINATED | Results posted: 2025-01-23